Goldman Sachs
CARM

Goldman Sachs’s Carisma Therapeutics CARM Stock Holding History

Goldman Sachs’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,410
Closed -$4.5K – 6474
2025
Q3 		$4.5K Buy
16,410
+3,384
+26% +$1.12K ﹤0.01% 6277
2025
Q2 		$5.1K Buy
+13,026
New +$3.49K ﹤0.01% 6019
2025
Q1 		– Sell
-21,381
Closed -$8.95K – 6095
2024
Q4 		$8.95K Buy
+21,381
New +$17.6K ﹤0.01% 5934
2024
Q3 		– Sell
-232,793
Closed -$354K – 5839
2024
Q2 		$354K Buy
+232,793
New +$347K ﹤0.01% 5010
2024
Q1 		– Sell
-10,519
Closed -$30.8K – 5581
2023
Q4 		$30.8K Sell
10,519
-2,230
-17% -$6.63K ﹤0.01% 5424
2023
Q3 		$53.9K Sell
12,749
-14,928
-54% -$94.5K ﹤0.01% 5272
2023
Q2 		$243K Buy
+27,677
New +$151K ﹤0.01% 5113
2022
Q4 		– Sell
-3,451
Closed -$29K – 5998
2022
Q3 		$29K Sell
3,451
-15,482
-82% -$211K ﹤0.01% 5870
2022
Q2 		$307K Sell
18,933
-1,750
-8% -$20K ﹤0.01% 5408
2022
Q1 		$250K Sell
20,683
-9,660
-32% -$135K ﹤0.01% 5758
2021
Q4 		$495K Buy
30,343
+20,180
+199% +$406K ﹤0.01% 5395
2021
Q3 		$161K Buy
10,163
+7,189
+242% +$345K ﹤0.01% 5790
2021
Q2 		$275K Sell
2,974
-4,375
-60% -$279K ﹤0.01% 5568
2021
Q1 		$382K Buy
7,349
+5,653
+333% +$267K ﹤0.01% 5292
2020
Q4 		$45K Sell
1,696
-5,725
-77% -$145K ﹤0.01% 5391
2020
Q3 		$208K Buy
+7,421
New +$148K ﹤0.01% 4895
2018
Q3 		– Sell
-953
Closed -$37K – 5568
2018
Q2 		$37K Buy
+953
New +$42K ﹤0.01% 5416
2017
Q2 		– Sell
-791
Closed -$35K – 6773
2017
Q1 		$35K Buy
+791
New +$33K ﹤0.01% 6379
2016
Q3 		– Sell
-667
Closed -$22K – 7024
2016
Q2 		$22K Sell
667
-1,424
-68% -$36K ﹤0.01% 6686
2016
Q1 		$13K Buy
2,091
+1,562
+295% +$21.6K ﹤0.01% 6844
2015
Q4 		$32K Sell
529
-592
-53% -$33.6K ﹤0.01% 6727
2015
Q3 		$54K Sell
1,121
-702
-39% -$43.3K ﹤0.01% 6759
2015
Q2 		$103K Buy
1,823
+1,047
+135% +$148K ﹤0.01% 6588
2015
Q1 		$138K Sell
776
-23
-3% -$5.03K ﹤0.01% 6265
2014
Q4 		$190K Sell
799
-42
-5% -$9.42K ﹤0.01% 6195
2014
Q3 		$187K Buy
+841
New +$200K ﹤0.01% 6215
2014
Q2 		– Sell
-539
Closed -$175K – 6981
2014
Q1 		$175K Buy
+539
New +$161K ﹤0.01% 6160

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
OP
ORG Partners Roanoke, Indiana $568M AUM 24.16% 1-Year Est. Return

Goldman Sachs's CARM Position: Q4 2025 in Review

Goldman Sachs sold out of Carisma Therapeutics (CARM) in Q4 2025, closing a stake of 16,410 shares — an estimated $4.5K sold.

Goldman Sachs first reported a position in CARM in Q1 2014 and held it in 27 quarters. The position peaked at $495K in Q4 2021. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • Goldman Sachs reported no remaining Carisma Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Goldman Sachs sold 16,410 Carisma Therapeutics shares in Q4 2025, an estimated $4.5K.
  • Goldman Sachs first reported a position in Carisma Therapeutics in Q1 2014 and held it in 27 quarters.
  • Goldman Sachs's Carisma Therapeutics position peaked at $495K in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.